Latest Market Research Reports

  Pharmaceutical CDMO Industry The global  pharmaceutical CDMO market  size is anticipated to reach USD 235.5 billion by 2030 and it is projected to grow at a CAGR of 7.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. A growing consumption of biopharmaceuticals, rising demand for advanced therapeutics, demand for orphan drug discovery, upsurge number of clinical trials and increasing demand for one-stop-shop CDMOS are anticipated to influence the global market positively. In addition, increasing pharmaceutical R&D investments can drive the market growth. As pharmaceutical companies invest more in R&D, they may seek external expertise and resources to accelerate drug development processes. CDMOs provide specialized services in drug development, manufacturing, and testing, making them valuable partners for pharmaceutical companies looking to outsource certain aspects of their R&D activities. Several players are investing in R&D ac...

  Pharmaceutical CDMO Industry Overview The global pharmaceutical Contract Development and Manufacturing Organization (CDMO) market was valued at approximately USD 146.0 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 7.2% from 2024 through 2030. This growth is primarily fueled by rising investments from CDMOs aimed at expanding new drug development capabilities and meeting the increasing demand for novel therapies. Several factors underpin this upward trend, including escalating investments in pharmaceutical Research & Development, a growing demand for genetic drugs, the rising incidence of cancer and age-related disorders, and an expanding need for advanced therapeutic options. Additionally, increased demand for biosimilars, biologics, personalized medicine, orphan drugs, companion diagnostics, and adaptive trial designs is anticipated to further drive the CDMO market. As pharmaceutical companies explore innovative treatment avenues, the ...

  Pharmaceutical CDMO Industry The global pharmaceutical Contract Development and Manufacturing Organization (CDMO) market was valued at approximately USD 146.0 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 7.2% from 2024 through 2030. This growth is primarily fueled by rising investments from CDMOs aimed at expanding new drug development capabilities and meeting the increasing demand for novel therapies. Several factors underpin this upward trend, including escalating investments in pharmaceutical Research & Development, a growing demand for genetic drugs, the rising incidence of cancer and age-related disorders, and an expanding need for advanced therapeutic options. Additionally, increased demand for biosimilars, biologics, personalized medicine, orphan drugs, companion diagnostics, and adaptive trial designs is anticipated to further drive the CDMO market. As pharmaceutical companies explore innovative treatment avenues, the need for ...